DOI: 10.3390/bioengineering10121368 ISSN: 2306-5354

Recent Advances in Optically Controlled PROTAC

Muzi Ouyang, Ying Feng, Hui Chen, Yanping Liu, Chunyan Tan, Ying Tan
  • Bioengineering

Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells. However, challenges related to insufficient target selectivity raise concerns about PROTAC toxicity toward normal cells. To address this issue, researchers are modifying PROTACs using various approaches to enhance their target specificity. This review highlights innovative optically controlled PROTACs as anti-cancer therapies currently used in clinical practice and explores the challenges associated with their efficacy and safety. The development of optically controlled PROTACs holds the potential to significantly expand the clinical applicability of PROTAC-based technology within the realm of drug discovery.

More from our Archive